TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Toxicity (DLT assessment)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUC24) of Talazoparib after multiple dosing under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Talazoparib after multiple dosing under fasted conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUC24) of Talazoparib after multiple dosing under fed conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Talazoparib after multiple dosing under fed conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep venous thrombosis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Clinically Significant Electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior on Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Reading the Mind in the Eyes Task (RMET)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rapid Automatized Naming (RAN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Affect Recognition Evaluation (DARE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of clinically defined febrile neutropenia (FN)
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous detachment of device
Endpoint domain: Adverse events/effects
Primary endpoint: Maxillary and mandibular arch width (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary and mandibular arch length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary and mandibular arch perimeter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in office Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differential microRNA detected by sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential mRNA detected by sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential lncRNA detected by sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Incomplete Excision of Dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: All cause stomach pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Human Activity Profile Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Outcome without complications
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of granuloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the number and proportion of times participants practiced vaginal or anal sex without a condom
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in the overall number of persons participants shared syringes or injection equipment with
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in the number and proportion of injections done with a syringe previously used by another person
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in the number and proportion of times participant used another person's equipment to prepare or divide drugs before injecting
Endpoint domain: Adverse events/effects
Primary endpoint: Count of Eligible Patients Agreeing to Receive a Dose of Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Clinical Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful crossing through lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dilatation with BLIMP or low profile balloon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relaxation Time in Ascending Colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pCO2 gap at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cytogenetic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doravirine Maximum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doravirine Oral Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late onset sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Yale-Brown Obsessive-Compulsive (Y-BOCS) rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Anxiety Questionnaire (BAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Whole body glucose counterregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Paroxysmal Sympathetic Hyperactivity Assessment Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%
Endpoint domain: Mortality/survival
Primary endpoint: Vitrectomy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in R-R variation during deep breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in response to Valsalva maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in 30:15 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in blood pressure response to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete response, partial response or stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lung recruitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to ART Among HIV Infected Members of Sero-discordant Couples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HIV-related Risk Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: proportion of patients with organ space surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Maximum Self-reported Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External validity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alterations in heart rate variability (HRV) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Cognition at 6 month
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Cognition at 1 year
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distribution of values of safety laboratory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with early discontinuation of vaccinations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of shared HIV epitopes targeted by T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confirmation of Tumor Targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUCtau for isavuconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for isavuconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau for lopinavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for lopinavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Zeltiq Device
Endpoint domain: Adverse events/effects
Primary endpoint: Change in elapsed seconds from call answer to start of T-CPR instructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from INVICTA lead-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: INVICTA lead electrical performance at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Low-Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional hip status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survivorship of the construct
Endpoint domain: Mortality/survival
Primary endpoint: Biopsy-proven allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating acyl-ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of focal sources and rotors in atrial segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient oriented composite outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of New Vital Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of HCV-infected Hepatocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP-reducing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in symptoms and signs of CHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte GRK2 mRNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patch Adhesion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular momentum during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood State Score on POMS-2 Test
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vigilance Score on Computer-based Test Using Random, Visual Stimulus: Proportion Correct (Out of 60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vigilance Score on Computer-based Test Using Random, Visual Stimulus: Mean Time to a Correct Hit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Salivary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proper use of Foradil Combi
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinically significant cardiac adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic and static lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number for adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of erythematous papule, vesicle, and/or eschar with or without underlying induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microagglutination (MA) titer that shows a ≥ 4-fold rise in antibody titer after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Global clinical improvement on each foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gas change parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Sit To Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Recovery (HRR%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder rate in patients achieving LDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom Medication Score (SMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Values of urethral pressure profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMC of RVNA Titer 14 Days After First Vaccination in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMC of RVNA Titer 14 Days After First Vaccination in Older Adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Length of Stay in the Emergency Department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: LDL control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tidal volume titration feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of Ferrlecit compared to oral iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical Global Assessment of Change (CGA-C) Responder Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peritoneal Metastasis Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Triglycerides Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfactory relief of abdominal discomfort or pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in % Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Physical Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful termination of pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Have Reversal of Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mouth pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival health of index teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Blood Pressure Average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of the ProAsk intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Utility of the ProAsk intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate or number of completed or attempted suicide
Endpoint domain: Mortality/survival
Primary endpoint: stabilometry variables eyes open
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stabilometry variables eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Anxiety Inventory (SAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: abnormal behavioral outcome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speed of lower teeth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Minimal Residual Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Walking function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of physical therapy treatments required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Weeks of Dynasplint treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Trough Functional Residual Capacity (FRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of subjects achieving >50% increase in clitoral engorgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxford hip and knee scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Enrolled Within 730 Days of First Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Available mRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients free of signs and symptoms of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in post-absorptive muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in combined amino acid and insulin stimulated muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with the targeted antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measles Seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emotional impact (electrodermal activity)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Control of DM2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving complete remission of keloid scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RLS symptoms (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RLS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Forced Expiratory Volume (FEV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Peak Respiratory Flow (PRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of malignant biliary-pancreatic tumor
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of adverse effects of dexmedetomidine
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of deferasirox and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Square Root of The Mean Squared Difference of Successive Normal to Normal R-R Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of imaging modalities for diagnosing HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant birth length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: quality of voice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short term pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biofeedback response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI parameters in the target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical variations in position, shape and size in the target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of severe skin toxicities (grade 2)
Endpoint domain: Adverse events/effects
Primary endpoint: Tremor Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of rifampin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of CSL312
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC0-inf) of CSL312
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum phosphorous concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes